TGTX up +7.10% percent right now. $TGTX High is at
Post# of 102250
Posted On: 11/10/2014 3:32:03 PM
TGTX up +7.10% percent right now. $TGTX High is at 12.47 and the Low 11.26 with current volume of 316,734.
Recent News posted below.
TGTX Tg Therapeutics Recent Headline News
TG Therapeutics reports November 11
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:10PM CST
TGTX: 12.46 (+1.19)
TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Fri Nov 07, 3:00PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that a conference call will be held on Tuesday, November 11, 2014 at 8:30am ET to discuss results for the third quarter of 2014 and provide a business outlook for the remainder of the year. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 12.46 (+1.19)
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:45AM CST
Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation
TGTX: 12.46 (+1.19)
Strong On High Relative Volume: TG Therapeutics (TGTX)
at The Street - Mon Oct 27, 9:00AM CDT
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a strong on high relative volume candidate
TGTX: 12.46 (+1.19)
Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 12:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) earned a $550,000 milestone payment from partner Merck (MRK) on the EU approval of Noxafil (posaconazole) for infusion.
MRK: 58.85 (-0.49), TGTX: 12.46 (+1.19), LGND: 54.98 (+1.04), AMGN: 163.06 (+2.81)
TG Therapeutics reports exercise of its option to license the global rights to TGR-1202
M2 - Wed Sep 24, 6:17AM CDT
Biopharmaceutical company TG Therapeutics (NasdaqCM :TGTX) said on Tuesday that it has exercised its option to license the global rights to TGR-1202 from Rhizen Pharmaceuticals.
TGTX: 12.46 (+1.19)
Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Rhizen Pharmaceuticals S.A. today announced an out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG Therapeutics exercised its option for early conversion to a licensing agreement from a 50:50 joint venture partnership.
TGTX: 12.46 (+1.19)
TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
GlobeNewswire - Tue Sep 23, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the Company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A ("Rhizen"
. The Company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the Company's license option.
TGTX: 12.46 (+1.19)
Nasdaq stocks posting largest percentage increases
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AMBA: 49.10 (+1.96), PRSC: 38.09 (-0.39), PERI: 5.83 (+0.08), RJET: 13.09 (+0.49), MSON: 11.03 (-0.77), QDEL: 27.98 (+0.11), ISRL: 139.53 (+2.03), TGTX: 12.46 (+1.19), RENT: 81.03 (+1.35), NYNY: 7.75 (+0.01), YRCW: 24.44 (+0.47), EMKR: 5.20 (unch), PODD: 44.71 (+1.66), AUXL: 32.79 (+0.04), APOG: 43.99 (+0.01), IDSY: 6.39 (-0.15)
TG Therapeutics (TGTX) in Focus: Stock Gains 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:46AM CDT
TG Therapeutics (TGTX) was a big mover last session, with shares rising over 16% on the day.
ICUI: 71.32 (+0.16), ABAX: 52.76 (+1.13), TGTX: 12.46 (+1.19), EGRX: 13.40 (+0.92)
TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia
GlobeNewswire - Mon Sep 15, 6:08AM CDT
Overall Response Rate (ORR) to be the Primary Endpoint to Support Accelerated Approval with Progression-Free Survival (PFS) to Support Full Approval
TGTX: 12.46 (+1.19)
UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 3:28PM CDT
In a release issued earlier today by TG Therapeutics, Inc. (Nasdaq:TGTX), please note the company's scheduled presentation time has changed to 1:15 PM ET, from 1:40 PM ET previously. The updated release follows:
TGTX: 12.46 (+1.19)
TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:12AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 16 Annual Rodman & Renshaw Global Investment Conference being held at the New York Palace Hotel. Mr. Weiss' presentation is scheduled to take place on Tuesday, September 9, 2014 at 1:40 PM ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section of the Company's website at www.tgtherapeutics.com.
TGTX: 12.46 (+1.19)
TG Therapeutics (TGTX) Worth Watching: Stock Up 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:44AM CDT
TG Therapeutics (TGTX) was a big mover last session, as the company saw its shares rise over 9% on the day.
ICUI: 71.32 (+0.16), ABAX: 52.76 (+1.13), TGTX: 12.46 (+1.19), ATRC: 17.60 (+0.74)
Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.
TGTX: 12.46 (+1.19), LGND: 54.96 (+1.02), AMGN: 163.06 (+2.81)
TG Therapeutics Announces Novel "Chemo-free" Triple Therapy Combination Clinical Study for Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies
GlobeNewswire - Fri Aug 15, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced the commencement of a novel triple therapy clinical study that combines the Company's two experimental drugs, TG-1101, a glycoengineered anti-CD20 monoclonal antibody, and TGR-1202 (ublituximab), a PI3K delta inhibitor, with the marketed BTK-inhibitor, ibrutinib (Imbruvica(R)). This is the first time that a BTK-inhibitor and a PI3k delta inhibitor have been used in combination with each other in patients. The trial is being led by Drs. Susan O'Brien and Nathan Fowler at MD Anderson, and Drs. Julie Vose and Matt Lunning of University of Nebraska, and will be run as a component of the previously announced and on-going Phase 1 study of the combination of TG-1101 and TGR-1202. The study will utilize fixed doses of TG-1101 and ibrutinib and will provide for dose escalation of TGR-1202.
TGTX: 12.46 (+1.19)
Falling Earnings Estimates Signal Weakness Ahead for TG Therapeutics (TGTX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 7:27AM CDT
TG Therapeutics has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
CSII: 29.70 (+0.34), ABAX: 52.76 (+1.13), TGTX: 12.46 (+1.19), ATRC: 17.60 (+0.74)
This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 26, 12:32PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
INO: 11.13 (-0.10), SAGE: 37.03 (-1.69), GILD: 107.18 (+0.73), TGTX: 12.46 (+1.19), PBYI: 242.25 (+5.36)
Recent News posted below.
TGTX Tg Therapeutics Recent Headline News
TG Therapeutics reports November 11
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:10PM CST
TGTX: 12.46 (+1.19)
TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Fri Nov 07, 3:00PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that a conference call will be held on Tuesday, November 11, 2014 at 8:30am ET to discuss results for the third quarter of 2014 and provide a business outlook for the remainder of the year. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 12.46 (+1.19)
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:45AM CST
Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation
TGTX: 12.46 (+1.19)
Strong On High Relative Volume: TG Therapeutics (TGTX)
at The Street - Mon Oct 27, 9:00AM CDT
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a strong on high relative volume candidate
TGTX: 12.46 (+1.19)
Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 12:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) earned a $550,000 milestone payment from partner Merck (MRK) on the EU approval of Noxafil (posaconazole) for infusion.
MRK: 58.85 (-0.49), TGTX: 12.46 (+1.19), LGND: 54.98 (+1.04), AMGN: 163.06 (+2.81)
TG Therapeutics reports exercise of its option to license the global rights to TGR-1202
M2 - Wed Sep 24, 6:17AM CDT
Biopharmaceutical company TG Therapeutics (NasdaqCM :TGTX) said on Tuesday that it has exercised its option to license the global rights to TGR-1202 from Rhizen Pharmaceuticals.
TGTX: 12.46 (+1.19)
Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Rhizen Pharmaceuticals S.A. today announced an out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG Therapeutics exercised its option for early conversion to a licensing agreement from a 50:50 joint venture partnership.
TGTX: 12.46 (+1.19)
TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
GlobeNewswire - Tue Sep 23, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the Company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A ("Rhizen"
. The Company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the Company's license option. TGTX: 12.46 (+1.19)
Nasdaq stocks posting largest percentage increases
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AMBA: 49.10 (+1.96), PRSC: 38.09 (-0.39), PERI: 5.83 (+0.08), RJET: 13.09 (+0.49), MSON: 11.03 (-0.77), QDEL: 27.98 (+0.11), ISRL: 139.53 (+2.03), TGTX: 12.46 (+1.19), RENT: 81.03 (+1.35), NYNY: 7.75 (+0.01), YRCW: 24.44 (+0.47), EMKR: 5.20 (unch), PODD: 44.71 (+1.66), AUXL: 32.79 (+0.04), APOG: 43.99 (+0.01), IDSY: 6.39 (-0.15)
TG Therapeutics (TGTX) in Focus: Stock Gains 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:46AM CDT
TG Therapeutics (TGTX) was a big mover last session, with shares rising over 16% on the day.
ICUI: 71.32 (+0.16), ABAX: 52.76 (+1.13), TGTX: 12.46 (+1.19), EGRX: 13.40 (+0.92)
TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia
GlobeNewswire - Mon Sep 15, 6:08AM CDT
Overall Response Rate (ORR) to be the Primary Endpoint to Support Accelerated Approval with Progression-Free Survival (PFS) to Support Full Approval
TGTX: 12.46 (+1.19)
UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 3:28PM CDT
In a release issued earlier today by TG Therapeutics, Inc. (Nasdaq:TGTX), please note the company's scheduled presentation time has changed to 1:15 PM ET, from 1:40 PM ET previously. The updated release follows:
TGTX: 12.46 (+1.19)
TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:12AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 16 Annual Rodman & Renshaw Global Investment Conference being held at the New York Palace Hotel. Mr. Weiss' presentation is scheduled to take place on Tuesday, September 9, 2014 at 1:40 PM ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section of the Company's website at www.tgtherapeutics.com.
TGTX: 12.46 (+1.19)
TG Therapeutics (TGTX) Worth Watching: Stock Up 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:44AM CDT
TG Therapeutics (TGTX) was a big mover last session, as the company saw its shares rise over 9% on the day.
ICUI: 71.32 (+0.16), ABAX: 52.76 (+1.13), TGTX: 12.46 (+1.19), ATRC: 17.60 (+0.74)
Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.
TGTX: 12.46 (+1.19), LGND: 54.96 (+1.02), AMGN: 163.06 (+2.81)
TG Therapeutics Announces Novel "Chemo-free" Triple Therapy Combination Clinical Study for Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies
GlobeNewswire - Fri Aug 15, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced the commencement of a novel triple therapy clinical study that combines the Company's two experimental drugs, TG-1101, a glycoengineered anti-CD20 monoclonal antibody, and TGR-1202 (ublituximab), a PI3K delta inhibitor, with the marketed BTK-inhibitor, ibrutinib (Imbruvica(R)). This is the first time that a BTK-inhibitor and a PI3k delta inhibitor have been used in combination with each other in patients. The trial is being led by Drs. Susan O'Brien and Nathan Fowler at MD Anderson, and Drs. Julie Vose and Matt Lunning of University of Nebraska, and will be run as a component of the previously announced and on-going Phase 1 study of the combination of TG-1101 and TGR-1202. The study will utilize fixed doses of TG-1101 and ibrutinib and will provide for dose escalation of TGR-1202.
TGTX: 12.46 (+1.19)
Falling Earnings Estimates Signal Weakness Ahead for TG Therapeutics (TGTX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 7:27AM CDT
TG Therapeutics has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
CSII: 29.70 (+0.34), ABAX: 52.76 (+1.13), TGTX: 12.46 (+1.19), ATRC: 17.60 (+0.74)
This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 26, 12:32PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
INO: 11.13 (-0.10), SAGE: 37.03 (-1.69), GILD: 107.18 (+0.73), TGTX: 12.46 (+1.19), PBYI: 242.25 (+5.36)
(0)
(0)Scroll down for more posts ▼